Macrolide maintenance therapy in patients with bronchiectasis significantly reduces the risk for major adverse cardiovascular events.

We came across a bullish thesis on Verona Pharma plc (VRNA) on Value Investing Subreddit Page by loud_keyb. In this article, ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024More prescriptions filled through February ...

Q4 2024 Earnings Call Transcript February 27, 2025 Verona Pharma plc misses on earnings expectations. Reported EPS is $-0.4 ...

Inogen shows solid B2B growth, but guidance and margin issues hurt sentiment. Learn why INGN stock is a speculative play with ...

Learn about idiopathic pulmonary fibrosis, its symptoms, diagnosis, and treatment options for managing this lung disease.

The nightly recitation of the rosary for Pope Francis and for all the sick "is a beautiful gesture" of affection and of faith, said Cardinal Leonardo Sandri. "Anyone can come. Praying together is a ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...

Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share1 of $6.

The increasing prevalence of nontuberculous mycobacteria (NTM) infections worldwide poses significant public health challenges, underscored by high fatality ...

Acute respiratory insufficiency is a condition in which the respiratory system is unable to provide adequate oxygen to the ...

Byondis has filed its HER2-targeting antibody-drug conjugate (ADC) trastuzumab duocarmazine in the US and Europe, setting up possible approvals next year and a showdown with heavyweight ...